Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

What symbol and exchange does Cardiff Oncology shares trade?

Cardiff Oncology trades on the NASDAQ stock market under the symbol CRDF.

What is Cardiff Oncology stock price doing today?

As of October 22, 2026, CRDF stock price declined to $0.93 with 189,396 million shares trading.

What is Cardiff Oncology's Beta?

CRDF has a beta of 3.05, meaning it tends to be more sensitive to market movements. CRDF has a correlation of 0.15 to the broad based SPY ETF.

How much is Cardiff Oncology worth?

CRDF has a market cap of $72.19 million. This is considered a Micro Cap stock.

How much money does Cardiff Oncology make?

Last quarter Cardiff Oncology reported $104,000 in Revenue and -$.14 earnings per share. This beat revenue expectation by $35,776 and exceeded earnings estimates by $.02.

What is the highest and lowest price Cardiff Oncology traded in the last 3 year period?

In the last 3 years, CRDF traded as high as $6.42 and as low as $.76.

What are the top ETFs holding Cardiff Oncology?

The top ETF exchange traded funds that CRDF belongs to (by Net Assets): VTI, VXF, IWC.

Is Cardiff Oncology (CRDF) a good investment?

CRDF has underperformed the market in the last year with a price return of -57.0% while the SPY ETF gained +15.5%. However, in the short term, CRDF had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.9% vs +2.5% return in SPY. But in the last 2 weeks, CRDF shares have been beat by the market, returning -12.5% compared to an SPY return of -1.3%.

What are the support and resistance levels for Cardiff Oncology (CRDF)?

CRDF support price is $.90 and resistance is $.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRDF shares will trade within this expected range on the day.